FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580496529> ?p ?o ?g. }

• W2580496529 endingPage "269" @default.
• W2580496529 startingPage "260" @default.
• W2580496529 abstract "Background Antiplatelet (AP) medication use is common among trauma patients and is associated with poor outcomes. Management options for platelet dysfunction in trauma patients are controversial, expensive, and potentially harmful. Although light transmission platelet aggregometry is considered the standard test to assess platelet function, it is cumbersome and not generally available. Currently, there are no widely accepted platelet function point-of-care tests for acute trauma. Study design Prospective observational study from 2014 to 2015. Baseline Multiplate aggregometry aspirin area under the platelet aggregation curve (ASPI AUC), Thrombelastography Platelet Mapping percent inhibition of arachidonic acid (TEG-PM AA), and VerifyNow Aspirin Test (ARU) were compared for ability to detect any AP medication use (aspirin or clopidogrel), platelet dysfunction, and identify patients at risk for intracranial hemorrhage (ICH) progression by calculating the area under receiver operating characteristic curves (AUC), sensitivity, specificity, and positive and negative predictive values. Adenosine diphosphate assays were similarly evaluated. Results Sixty-four patients were enrolled, 25 were taking AP medications. AP patients were older (71.6 versus 35.0 y, P < 0.001) and received more platelet transfusions, but other baseline characteristics were similar. Median ASPI AUC (22.0 versus 53.5 P < 0.001) and VerifyNow ARU (503.5 versus 629.0, P < 0.001) were lower, whereas TEG-PM AA (51.8% versus 18.3%, P < 0.001) was higher in AP patients. Multiplate ASPI AUC, TEG-PM AA percent inhibition, and VerifyNow ARU could identify AP medication use (AUC: 0.90, 0.77, and 0.90, respectively). Adenosine diphosphate assays did not correlate with AP medication use in this population. TEG-PM AA percent inhibition and VerifyNow ARU correlated well with Multiplate ASPI AUC to identify platelet dysfunction (AUC: 0.78, 0.89, respectively). ICH occurred in 29 patients; 12 of which had progression of their injury. ASPI AUC (AUC: 0.50) and VerifyNow ARU (AUC: 0.59) did not correlate, and TEG-PM AA percent inhibition (AUC: 0.66) minimally correlated with progression. Conclusions Multiplate, TEG-PM, and VerifyNow are useful point-of-care tests which identify AP medication use and platelet dysfunction in trauma patients. Initial TEG-PM AA percent inhibition may be associated with risk for ICH progression. However, additional large, prospective studies are needed." @default.
• W2580496529 created "2017-02-03" @default.
• W2580496529 creator A5003836080 @default.
• W2580496529 creator A5009104795 @default.
• W2580496529 creator A5012661227 @default.
• W2580496529 creator A5012781300 @default.
• W2580496529 creator A5024576216 @default.
• W2580496529 creator A5035406174 @default.
• W2580496529 creator A5041277987 @default.
• W2580496529 creator A5053740783 @default.
• W2580496529 creator A5057686497 @default.
• W2580496529 creator A5060967302 @default.
• W2580496529 creator A5065687656 @default.
• W2580496529 creator A5075973069 @default.
• W2580496529 date "2017-05-01" @default.
• W2580496529 modified "2023-09-27" @default.
• W2580496529 title "Assessment of three point-of-care platelet function assays in adult trauma patients" @default.
• W2580496529 cites W1486625032 @default.
• W2580496529 cites W1968427141 @default.
• W2580496529 cites W1968931774 @default.
• W2580496529 cites W1970569414 @default.
• W2580496529 cites W1988769064 @default.
• W2580496529 cites W1996681677 @default.
• W2580496529 cites W2008016809 @default.
• W2580496529 cites W2009380060 @default.
• W2580496529 cites W2042212990 @default.
• W2580496529 cites W2053232006 @default.
• W2580496529 cites W2061363260 @default.
• W2580496529 cites W2069053100 @default.
• W2580496529 cites W2074924882 @default.
• W2580496529 cites W2080197149 @default.
• W2580496529 cites W2083266350 @default.
• W2580496529 cites W2086891666 @default.
• W2580496529 cites W2091685079 @default.
• W2580496529 cites W2094778417 @default.
• W2580496529 cites W2095221498 @default.
• W2580496529 cites W2095631860 @default.
• W2580496529 cites W2109695444 @default.
• W2580496529 cites W2110278285 @default.
• W2580496529 cites W2116209940 @default.
• W2580496529 cites W2124274852 @default.
• W2580496529 cites W2132793593 @default.
• W2580496529 cites W2133802104 @default.
• W2580496529 cites W2136715209 @default.
• W2580496529 cites W2146070567 @default.
• W2580496529 cites W2161887684 @default.
• W2580496529 cites W2314604034 @default.
• W2580496529 cites W2328913428 @default.
• W2580496529 cites W2416021869 @default.
• W2580496529 doi "https://doi.org/10.1016/j.jss.2017.01.008" @default.
• W2580496529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28550916" @default.
• W2580496529 hasPublicationYear "2017" @default.
• W2580496529 type Work @default.
• W2580496529 sameAs 2580496529 @default.
• W2580496529 citedByCount "43" @default.
• W2580496529 countsByYear W25804965292018 @default.
• W2580496529 countsByYear W25804965292019 @default.
• W2580496529 countsByYear W25804965292020 @default.
• W2580496529 countsByYear W25804965292021 @default.
• W2580496529 countsByYear W25804965292022 @default.
• W2580496529 countsByYear W25804965292023 @default.
• W2580496529 crossrefType "journal-article" @default.
• W2580496529 hasAuthorship W2580496529A5003836080 @default.
• W2580496529 hasAuthorship W2580496529A5009104795 @default.
• W2580496529 hasAuthorship W2580496529A5012661227 @default.
• W2580496529 hasAuthorship W2580496529A5012781300 @default.
• W2580496529 hasAuthorship W2580496529A5024576216 @default.
• W2580496529 hasAuthorship W2580496529A5035406174 @default.
• W2580496529 hasAuthorship W2580496529A5041277987 @default.
• W2580496529 hasAuthorship W2580496529A5053740783 @default.
• W2580496529 hasAuthorship W2580496529A5057686497 @default.
• W2580496529 hasAuthorship W2580496529A5060967302 @default.
• W2580496529 hasAuthorship W2580496529A5065687656 @default.
• W2580496529 hasAuthorship W2580496529A5075973069 @default.
• W2580496529 hasConcept C126322002 @default.
• W2580496529 hasConcept C23131810 @default.
• W2580496529 hasConcept C2777399203 @default.
• W2580496529 hasConcept C2777628954 @default.
• W2580496529 hasConcept C2777664302 @default.
• W2580496529 hasConcept C2777849778 @default.
• W2580496529 hasConcept C2910686401 @default.
• W2580496529 hasConcept C2993802102 @default.
• W2580496529 hasConcept C3018697912 @default.
• W2580496529 hasConcept C42219234 @default.
• W2580496529 hasConcept C71924100 @default.
• W2580496529 hasConcept C76318530 @default.
• W2580496529 hasConcept C89560881 @default.
• W2580496529 hasConcept C90924648 @default.
• W2580496529 hasConceptScore W2580496529C126322002 @default.
• W2580496529 hasConceptScore W2580496529C23131810 @default.
• W2580496529 hasConceptScore W2580496529C2777399203 @default.
• W2580496529 hasConceptScore W2580496529C2777628954 @default.
• W2580496529 hasConceptScore W2580496529C2777664302 @default.
• W2580496529 hasConceptScore W2580496529C2777849778 @default.
• W2580496529 hasConceptScore W2580496529C2910686401 @default.
• W2580496529 hasConceptScore W2580496529C2993802102 @default.
• W2580496529 hasConceptScore W2580496529C3018697912 @default.
• W2580496529 hasConceptScore W2580496529C42219234 @default.

• next